Inventor

MADDON PAUL J

US48 patents

⚠️ This page may combine multiple inventors who share the name “MADDON PAUL J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

MADDON PAUL J

PROGENICS PHARM INC

Method for preventing HIV-1 infection of CD4+ cells

Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion

Method for preventing HIV-1 infection of CD4+ cells

Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof

Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same

Stabilized viral envelope proteins and uses thereof

Compositions and methods for inhibition of HIV-1 infection

Methods for inhibiting HIV-1 infection

Compositions and methods for inhibition of HIV-1 infection

Compounds capable of inhibiting HIV-1 infection

Methods for inhibiting HIV-1 infection

Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing same

Anti-CCR5 antibody

Stabilized viral envelope proteins and uses thereof

Stabilized viral envelope proteins and uses thereof

CD4-gamma2 and CD4-IGG2 chimeras

HIV-1 antigens, antibody compositions related thereto, and therapeutic and prophylactic uses thereof

Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof

Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 Immunoconjugates, and uses thereof

Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteins

Uses of CD4-gamma2 and CD4-IgG2 chimeras

HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof

Anti-CCR5 antibody

Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection

Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof

CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion

Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion

Methods for inhibiting HIV-1 envelope glycoprotein-medicated membrane fusion

Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists

Methods of inhibiting human immunodeficiency virus infection through the administration of synergistic combinations of anti-CCR5 monoclonal antibodies, fusion inhibitors, and CD4-GP120 binding inhibitors

Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection

Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof

Cells expressing a CD4-IgG2 chimeric heterotetramer

UNIV COLUMBIA

Soluble forms of the t cell surface protein cd4

Derivatives of soluble T-4

DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS

DNA encoding the T cell surface protein CD4 and use of fragments of CD4 in the treatment of AIDS

Internal deletion mutants of soluble T4(CD4)

DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS

DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS

Derivatives of soluble T-4

MADDON PAUL J

PSMA antibodies and uses thereof

Compositions of PSMA antibodies

PSMA antibodies and uses thereof

PDL BIOPHARMA INC

Anti-CCR5 antibody

PSMA DEV COMPANY LLC

PSMA antibodies and protein multimers

OLSON WILLIAM C

Methods for inhibiting HIV-1 replication involving the administration of an anti-CCR5 receptor monoclonal antibody and small molecule CCR5 receptor antagonist

CYTODYN INC

Methods for reducing viral load in HIV-1 infected patients